Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Medacta Group SA    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Medacta : Expands its Knee Offerings with New SensiTiN System with Low Metal Ion Release

10/19/2020 | 01:00pm EST

EQS Group-News: Medacta Group SA / Key word(s): Product Launch
Medacta Expands its Knee Offerings with New SensiTiN System with Low Metal Ion Release

19.10.2020 / 19:00


Media release

Medacta Expands its Knee Offerings with New SensiTiN System with Low Metal Ion Release

CASTEL SAN PIETRO, 19 October 2020 - Medacta announced today the official launch of the new SensiTiN system in the European market. This system includes titanium niobium nitride (TiNbN) coated knee implants for use in total knee replacement and revision procedures.

Medacta SensiTiN system has been designed to reduce metal ion release. Leveraging the clinical experience gained in Europe with GMK Sphere and GMK Primary TiNbN coated implants, Medacta has decided to extend this technology to its revision system (GMK Hinge SensiTiN and GMK Revision SensiTiN) for which it has recently received the CE marking. Following this important registration, the SensiTiN system is now a complete system that allows for treating a larger number of patients, from primary to complex revision cases. Moreover, the system will become even more complete with the upcoming introduction of the Medacta TiNbN coated partial knee system.

Pieter Ackerman, M.D., has recently performed a surgery utilizing a GMK Hinge SensiTiN at Az Sint-Vincentius Hospital in Deinze, Belgium. "I am very excited about the new SensiTiN system, as it dramatically reduces the exposure of patients to metallic ions," said Dr. Ackerman. "As the most advanced technique to limit the release of ions in total knee replacement, the titanium niobium nitride coating minimizes the risk of adverse reactions, especially for patients with proven or suspected sensitivity to metal ions."

The SensiTiN system has now been extended to the entire GMK family for total knee replacement (from GMK Primary to GMK Revision and Hinge), retaining all the features of the Medacta GMK system. The GMK system includes versatile and comprehensive knee arthroplasty solutions designed to preserve joint functionality. The GMK instrumentation is designed to minimize complexity. Thanks to its modularity, the surgeon is able to better adapt their approach to different surgical scenarios.

Medacta provides surgeons with continuous support in the application of its knee portfolio and other products through the M.O.R.E. Institute, which offers comprehensive educational programs that aim to help surgeons get their patients back to their healthy and active lifestyles as safely and efficiently as possible.

Learn more about Medacta's knee portfolio at knee.medacta.com.


Contact
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch

About Medacta
Medacta is an international company specialized in the design and production of innovative orthopaedic products and the development of accompanying surgical techniques for joint replacement, spine surgery, and sports medicine. Established in 1999 in Switzerland, Medacta's products and surgical techniques are characterized by innovation. Medacta is a pioneer in developing new offerings on the basis of minimally invasive surgical techniques, in particular its Anterior Minimally Invasive Surgery (AMIS) technique for hip replacements. Medacta has leveraged its orthopaedic expertise and comprehensive understanding of the human body to develop the sophisticated MySolutions technology, which offers surgeons highly personalized pre-operative planning and implant placement methodologies by creating advanced personalized kinematic models and 3D planning tools for use in hip, knee, shoulder and spine procedures.



End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch,investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1141553

 
End of News EQS Group News Service

1141553  19.10.2020 

fncls.ssp?fn=show_t_gif&application_id=1141553&application_name=news&site_id=zonebourse_sftp

© EQS 2020
All news about MEDACTA GROUP SA
02/18MEDACTA  : First U.S. Anterior Cruciate Ligament Reconstruction with M-ARS ACL
PU
02/15MEDACTA  : Gets US FDA Nod for MyHip Planner, Verifier Tools
MT
02/15MEDACTA  : Adds the MyHip Planner and the MyHip Verifier Tools to its Personaliz..
PU
02/15EQS-NEWS  : Medacta Adds the MyHip Planner and the MyHip Verifier Tools to its P..
DJ
01/25MEDACTA  : Octavian Lifts Price Target on Medacta Group, Maintains Buy Recommend..
MT
01/21MEDACTA  : FY20 Revenue Slips 3% Amid Growth Slump Across Product Line
MT
01/21MEDACTA  : 2020 Preliminary unaudited top-line figures Read More >
PU
01/21EQS-ADHOC  : 2020 Preliminary unaudited top-line -2-
DJ
01/21MEDACTA  : 2020 Preliminary unaudited top-line figures
EQ
01/04MEDACTA  : announces the results of today's Extraordinary General Meeting Read M..
PU
More news
Financials
Sales 2020 300 M 358 M 358 M
Net income 2020 29,7 M 35,4 M 35,4 M
Net Debt 2020 113 M 135 M 135 M
P/E ratio 2020 60,1x
Yield 2020 0,45%
Capitalization 1 810 M 2 156 M 2 158 M
EV / Sales 2020 6,40x
EV / Sales 2021 5,37x
Nbr of Employees 1 126
Free-Float 30,5%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 80,41 €
Last Close Price 90,51 €
Spread / Highest target 10,8%
Spread / Average Target -11,2%
Spread / Lowest Target -35,4%
EPS Revisions
Managers and Directors
NameTitle
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Riccardo Braglia Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDACTA GROUP SA15.75%2 156
ABBOTT LABORATORIES5.95%207 712
MEDTRONIC PLC-1.60%159 352
BECTON, DICKINSON AND COMPANY-1.51%71 609
ALIGN TECHNOLOGY, INC.-2.61%42 452
HOYA CORPORATION-16.75%40 288